Parameter
| Biomarker | Galectin-3 (Gal-3) | Full name | Galectin-3 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~26 kDa | Core Functional Dimensions | Prognostic assessment and fibrosis monitoring | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Macrophages, hepatocytes, myocardium | Test Sample / Technology Platform | Plasma (ELISA) | ||
| Pathobiological Mechanisms | Secreted by macrophages, it promotes myocardial fibrosis by cross-linking extracellular matrix and participates in the activation of inflammation-fibrosis axis in the progression of HF | ||||
| Clinical Availability Status | Clinical validation/guideline mentions: -ESC guideline (2021) recommended for HF prognostic stratification (class Ⅱb recommendation); - BIOSTAT-CHF research confirms its prognostic value of HFpEF than HFrEF | ||||
| Notes and Dynamics | HFpEF Gal-3 increased in patients with more prominent (AUC = 0.74), and pulmonary capillary wedge pressure (PCWP) positive correlation (r = 0.42); In patients with chronic HF, Gal-3>17ng/ml suggested a 2-year mortality rate of HR=1.89, and the change trend could predict the treatment response. And SGLT2 inhibitor can decrease the Gal-3 levels, reflect the anti fibrosis drug | ||||